Ondansetron Hikma

Ondansetron, the active ingredient in Ondansetron Hikma, is a 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It prevents chemotherapy‑induced, postoperative and radiation‑induced nausea and vomiting in patients undergoing such treatments.

GNH USA supplies Ondansetron Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on the serotonin 5‑HT3 receptor pathway to control nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Postoperative nausea and vomiting: helps prevent nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: mitigates nausea and vomiting associated with therapeutic radiation.

Common Side Effects: - Headache: mild to moderate headache reported. - Constipation: reduced bowel motility leading to constipation. - Diarrhoea: occasional loose stools. - Fatigue: general tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm changes. - Severe allergic reaction: anaphylaxis, rash, swelling. - Serotonin syndrome: rare when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

Precautions should be taken to ensure safe use of ondansetron injectable. - Cardiac monitoring: assess baseline ECG in patients with known cardiac disease. - Electrolyte balance: correct hypokalemia, hypomagnesemia before use. - Drug interactions: review concomitant serotonergic drugs. - Pregnancy: use only if benefit outweighs risk; data limited. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension and loss of consciousness. - Certain antiarrhythmics (e.g., quinidine): increase risk of QT prolongation. - Other serotonergic agents (e.g., SSRIs, MAOIs): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Anticholinergic drugs: may enhance constipation.